Carbiotix is an award winning pre-clinical stage therapeutics company leveraging low-cost gut
health testing and microbiome modulators to unlock the potential of the gut microbiome to
address a range of chronic and metabolic diseases.
Carbiotix low-cost gut health test products are offered to consumers and companies as a means to cost
effectively track gut health over time and overcome the natural variability associated with gut microbiome testing.
The gut health tests serve as both a therapeutic discovery and diagnostic platform as well as assist
with verifying and amplifying the efficacy of Carbiotix therapeutics.
Carbiotix is developing a new generation of microbiome modulators based on proprietary second-generation
soluble fibers, isolated bacterial strains and novel delivery mechanisms. This approach will allow Carbiotix
to target a broad range of chronic and metabolic conditions by optimizing a person’s microbiome metabolic
profile with high efficacy propriety therapeutic solutions.
It is the belief of Carbiotix that activity within the gut microbiome is more important than the presence of
specific bacteria species. As such, the company is focused on engineering microbiome modulators to restore and optimize
gut microbiome metabolic processes and thereby obtain a desired therapeutic effect through an improved metabolic profile.